brainscienceblogs.com

we know psychiatry.

Press Release: Placebo Response in Depression: A Perspective for Clinical Practice

NEW AND NOTEWORTHY:

Newly Published:
A Major Change of Prescribing Pattern in Absence of Adequate Evidence: Benzodiazepines Versus Newer Antidepressants in Anxiety Disorders
By Patricia Berney, MD, Demian Halperin, MD, Rodrigo Tango, MD, Isabelle Daeniker-Dayer, MD and
Pierre Schulz, MD
Psychopharmacology Bulletin. 2008;41(3):39–47

Are SNRIs More Effective than SSRIs? A Review of the Current State of the Controversy
By Michael E. Thase, MD. Psychopharmacol Bull. 2008; 41(2):58-85.

Criteria for Defining Symptomatic and Sustained Remission in Bipolar I Disorder: a Post-Hoc Analysis of
a 26-Week Aripiprazole Study (Study CN138-010)
By Prakash S. Masand, MD, James Eudicone, MS, Andrei Pikalov, MD, PhD, Robert D. McQuade, PhD, Ronald N. Marcus, MD, Estelle Vester-Blokland, MD and Berit X. Carlson, PhD. Psychopharmacology Bulletin. 2008;41(2):12-23.

Bipolar-I Depression Outpatient Treatment Quality and Costs in Usual Care Practice
By Alisa B. Busch, MD, MS, Richard G. Frank, PhD, and Gary Sachs, MD. Psychopharmacology Bulletin. 2008;41(2):24-39.

Addressing Methodological Issues in Studying Antidepressant Onset Efficacy Using Prespecified
Sensitivity Analyses
By Ilya Lipkovich, PhD, Craig H. Mallinckrodt, PhD, Apurva Prakash, BA, and Andrew A. Nierenberg, MD. Psychopharmacology Bulletin. 2008;41(2):40-54.

Continuous Positive Airways Pressure Treatment in a Patient with Sleep Apnea—Hypopnea Syndrome and Coexisting Bipolar Disorder
By Georgia Trakada, MD, Pashalis Steiropoulos, MD, and Demosthenes Bouros, MD, FCCP. Psychopharmacology Bulletin. 2008;41(2):89-92.

Just in: Integration of depression and hypertension treatment: a pilot, randomized controlled trial.
Ann Fam Med. 2008;6(4):295-301

Just in: New Data in the Recognition and Management of Bipolar Disorder.
Christoph U. Correll, MD; Terence A. Ketter, MD; Roy H. Perlis, MD, MSc; Michael E. Thase, MD

While all readers are welcome to explore brainscience.com, this site is designed for mental healthrofessionals with a keen interest in the brain sciences. Many articles are technical, and originate from peer-review journals. Best of luck and good reading. —The Editors

Michael E. Thase, MD, Editor-In-ChiefA Long-Revered Resource in Academia

Published from 1965 until 1999 by the National Institute of Mental Health (NIMH), Psychopharmacology BULLETIN forged its path just as psychiatry itself was embarking on its golden era of treatment breakthroughs and recognition as a valid and independent field of medicine. Within months of MedWorks Media acquiring the rights to the title, the beloved Psychopharmacology BULLETIN was given a facelift, and a powerhouse Editor

The ABCs of Trends: A Mission of Influence

[ndexed in a variety of databases including Index Medicus and PubMed since 1966, Bulletin’s influential name carries with it a certain responsibility to make sense of the trends in medicine for clinicians. With the primary catalyst for cutting-edge remission treatment in anxiety and depression—Michael E. Thase, MD—on board as the new Editor, the Bulletin will cover evidence-based medicine as a section in every issue, along with original works on drug interactions and neuroscientific updates in translational work and imaging. Dr. Thase’s focus is on the future, on broadening the Bulletin’s scope, fostering an ability to engage readers actively, and expanding its already formidable sphere of influence in the field of neuropsychiatry. editorial board masthead